A special National Institutes of Health oversight panel will no longer review all gene therapy applications and will instead take on a broader advisory role, as the treatment quickly becomes an established form of medical care with no extraordinary risks.
NIH and FDA researchers increasingly depend on data from an array of sources, and they want to bring real-world evidence into their work. That includes the NIH's All of Us precision-medicine initiative.
The National Institutes of Health wants to gather data from 1 million people, including those historically underrepresented in medical research, to advance precision medicine and improve prevention and treatments.
A peek at who got a piece of the $1.3 trillion two-year omnibus spending bill.
It's Rare Disease Week and Rare Disease Day is Feb. 28, both of which are aimed at highlighting the difficulty and costliness of treating rare conditions.
President Donald Trump's fiscal 2019 budget blueprint includes a 21% reduction in HHS' overall budget. Beyond cuts to Medicare and Medicaid, smaller programs would also see their funding shrink.
The Senate health committee will get its first crack at assessing the Trump administration's implementation of last year's key bipartisan healthcare law.
As part of the All of Us research program, 10,000 volunteers' health indicators will be tracked by Fitbits, as the device straddles the line between consumer product and healthcare technology.
An appropriations subcommittee rejected a proposed multibillion-dollar cut to HHS funding over concerns that it could stymie medical innovation.
The Trump administration's 2018 budget proposed to merge the Agency for Healthcare Research and Quality with the National Institutes of Health. Experts say the move could benefit AHRQ if the consolidation is done right.
Dr. Norman E. Sharpless, director of UNC Lineberger Comprehensive Cancer Center, has been nominated to lead the National Cancer Institute, the largest division of the National Institutes of Health.
The 21st Century Cures Act signed by President Obama Tuesday has been ballyhooed as a major boost for NIH and cancer and brain research. But a closer look at the numbers reveals how little it offers—at a potentially high price.